News
PDSB
1.060
-2.75%
-0.030
Weekly Report: what happened at PDSB last week (0406-0410)?
Weekly Report · 1d ago
B. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)
TipRanks · 04/06 15:50
Why Is Vanguard Total Stock Market ETF (VTI) Up Today, 4/6/2026?
TipRanks · 04/06 13:08
Weekly Report: what happened at PDSB last week (0330-0403)?
Weekly Report · 04/06 09:06
PDS Biotechnology Earnings Call Highlights Clinical Momentum
TipRanks · 04/04 00:16
Vanguard Total Stock Market ETF (VTI) Daily Update, 4/3/26?
TipRanks · 04/03 13:27
Why Is Vanguard Total Stock Market ETF (VTI) Down Today, 4/2/26?
TipRanks · 04/02 12:14
Vanguard Total Stock Market ETF (VTI) Daily Snapshot — 4/1/26
TipRanks · 04/01 13:18
Why Is Vanguard Total Stock Market ETF (VTI) Rising Today, 3/31/26?
TipRanks · 03/31 14:43
PDS Biotechnology: Streamlined Phase 3 Design and Improved Financials Accelerate Path to Potential Approval
TipRanks · 03/31 10:37
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment
Seeking Alpha · 03/30 16:02
PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate
Benzinga · 03/30 13:41
Why Is Vanguard Total Stock Market ETF (VTI) Up Today, 3/30/26?
TipRanks · 03/30 13:13
PDS Biotechnology Reports Early Positive Results In Cancer Study, Tweaks Late-Stage Cancer Trial To Speed Up Potential Approval
Benzinga · 03/30 11:23
Earnings Scheduled For March 30, 2026
Benzinga · 03/30 11:11
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M
Benzinga · 03/30 11:08
PDS Biotechnology GAAP EPS of -$0.74
Seeking Alpha · 03/30 11:06
Options Volatility and Implied Earnings Moves Today, March 30, 2026
TipRanks · 03/30 11:05
PDS Biotech FY25 net loss narrows 8.29% to $34.5 million
Reuters · 03/30 11:04
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.